was trading higher after Citigroup upgraded the drugmaker to buy from hold. Merck was recently adding $1.88, or 4.4%, to $44.82.
was rising after a positive article in
over the weekend said the Botox maker could benefit from the trend of retired baby-boomers drawing on their nest eggs. The stock was climbing $1.77, or 1.6%, to $114.12.
was falling after the Food and Drug Administration said it will need additional clinical trial data before granting U.S. approval for the sale of the company's diabetes drug Galvus. Shares of Novartis were lower by $1.46, or 2.5%, to $57.19.
was downgraded as Wachovia lowered its rating on the company to market-perform from outperform. The stock was recently losing $1.67, or 2.6%, to $62.46.
Among health care winners Monday,
was recently up 2.4% to $19.96.
was tacking on 1.6% to $54.44.
was higher by 1% to $25.87.
tumbled 11.4% to $2.04.
was off 3.3% to $13.41.
eased by 1.7% to $63.21.